All In Biotech

Drug Trial Radar · NCT05385978

A Study of Distal Jejunal-release Dextrose in Obese Participants

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects

Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Nov 11, 2024

Study completion Nov 11, 2024

Sponsor

Lead sponsor
Aphaia Pharma US LLCIndustry
Sponsor type
Industry
First posted
May 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.

Conditions

  • Obese

Interventions

  • APHD-012Drug

    Distal jejunal-release dextrose beads (Aphaia technology, AT)

  • APHD-012PDrug

    Distal jejunal-release placebo beads

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from Baseline in Percent Weight Change Compared with PlaceboTime frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • LTD "Israeli-Georgian Medical Research Clinic Healthycore"

    Tbilisi, Georgia

  • LTD "Acad. G. Chapidze Emergency Cardiology Center"

    Tbilisi, Georgia

  • LTD "Diacor"

    Tbilisi, Georgia

  • LTD "National Institute of Endocrinology"

    Tbilisi, Georgia

  • LTD "Tbilisi Heart Center"

    Tbilisi, Georgia

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany

  • Universitätsklinikum Ruppin-Brandenburg

    Neuruppin, Germany

  • GCM Medilcal Group

    San Juan, Puerto Rico

  • FDI Clinical Research

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.